CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

Spirostan-3-Ol 10mg  | ≥98%

CSNpharm

Spirostan-3-ol is a stereoisomer of sarsasapogenin, a steroid glycoside isolated from plant materials with potential anti-tumor activity via apoptosis.

More Information Supplier Page

Spirostan-3-Ol 5mg  | ≥98%

CSNpharm

Spirostan-3-ol is a stereoisomer of sarsasapogenin, a steroid glycoside isolated from plant materials with potential anti-tumor activity via apoptosis.

More Information Supplier Page

Splitomicin 50mg  | ≥99%

CSNpharm

Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay.

More Information Supplier Page

Splitomicin 10mg  | ≥99%

CSNpharm

Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay.

More Information Supplier Page

Splitomicin 25mg  | ≥99%

CSNpharm

Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay.

More Information Supplier Page

SQ109 25mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ109 1mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ109 5mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ109 100mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ109 10mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ109 50mg  | ≥98%

CSNpharm

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM.

More Information Supplier Page

SQ22536 250mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SQ22536 25mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SQ22536 50mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SQ22536 100mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SQ22536 10mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SQ22536 5mg  | ≥99%

CSNpharm

SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

More Information Supplier Page

SR 202 5mg  | ≥99%

CSNpharm

SR 202 is a selective PPARγ antagonist which attenuates troglitazone-induced PPARγ transcriptional activity with IC50 value of 140μM. It inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo and improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.

More Information Supplier Page

SR 202 1mg  | ≥99%

CSNpharm

SR 202 is a selective PPARγ antagonist which attenuates troglitazone-induced PPARγ transcriptional activity with IC50 value of 140μM. It inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo and improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.

More Information Supplier Page

SR-3335 50mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 5mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 10mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 1mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 25mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR59230A 1mg  | ≥98%

CSNpharm

SR59230A is a potent and selective Adrenergic Receptor β3 antagonist with IC50 values of 40, 408, and 648nM for Adrenergic Receptor β3, β1 and β2, respectively. It shows blood-brain barrier penetrability.

More Information Supplier Page

SR59230A 50mg  | ≥98%

CSNpharm

SR59230A is a potent and selective Adrenergic Receptor β3 antagonist with IC50 values of 40, 408, and 648nM for Adrenergic Receptor β3, β1 and β2, respectively. It shows blood-brain barrier penetrability.

More Information Supplier Page

SR59230A 10mg  | ≥98%

CSNpharm

SR59230A is a potent and selective Adrenergic Receptor β3 antagonist with IC50 values of 40, 408, and 648nM for Adrenergic Receptor β3, β1 and β2, respectively. It shows blood-brain barrier penetrability.

More Information Supplier Page

SR59230A 100mg  | ≥98%

CSNpharm

SR59230A is a potent and selective Adrenergic Receptor β3 antagonist with IC50 values of 40, 408, and 648nM for Adrenergic Receptor β3, β1 and β2, respectively. It shows blood-brain barrier penetrability.

More Information Supplier Page

SR59230A 5mg  | ≥98%

CSNpharm

SR59230A is a potent and selective Adrenergic Receptor β3 antagonist with IC50 values of 40, 408, and 648nM for Adrenergic Receptor β3, β1 and β2, respectively. It shows blood-brain barrier penetrability.

More Information Supplier Page

SRT1720 2HCl 25mg  | ≥98%

CSNpharm

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%.

More Information Supplier Page

SRT1720 2HCl 50mg  | ≥98%

CSNpharm

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%.

More Information Supplier Page

SRT1720 2HCl 100mg  | ≥98%

CSNpharm

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%.

More Information Supplier Page

SSE15206 50mg  | ≥99%

CSNpharm

SSE15206 is a microtubule depolymerizing agent which inhibits microtubule polymerization both in biochemical and cellular assays by binding to colchicine site in tubulin. It causes aberrant mitosis resulting in G2/M arrest due to incomplete spindle formation.

More Information Supplier Page

SSE15206 10mg  | ≥99%

CSNpharm

SSE15206 is a microtubule depolymerizing agent which inhibits microtubule polymerization both in biochemical and cellular assays by binding to colchicine site in tubulin. It causes aberrant mitosis resulting in G2/M arrest due to incomplete spindle formation.

More Information Supplier Page